ALECTOR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.25 USD | +9.15% |
|
+3.14% | -34.21% |
| Sales 2024 * | 62.31M 4.99B | Sales 2025 * | 116M 9.31B | Capitalization | 506M 40.51B |
|---|---|---|---|---|---|
| Net income 2024 * | -201M -16.09B | Net income 2025 * | -129M -10.33B | EV / Sales 2024 * | -0.69 x |
| Net cash position 2024 * | 549M 43.94B | Net cash position 2025 * | 703M 56.28B | EV / Sales 2025 * | -1.69 x |
| P/E ratio 2024 * |
-2.45
x | P/E ratio 2025 * |
-3.4
x | Employees | 244 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alector, Inc.
More recommendations
More press releases
More news
| 1 day | +9.15% | ||
| 1 week | +3.14% | ||
| Current month | -12.79% | ||
| 1 month | -11.91% | ||
| 3 months | -13.08% | ||
| 6 months | -0.57% | ||
| Current year | -34.21% |
1 week
4.80
5.40
1 month
4.806.25
Current year
4.808.90
1 year
3.669.07
3 years
3.6643.32
5 years
3.6643.32
10 years
3.6643.32
| Managers | Title | Age | Since |
|---|---|---|---|
Arnon Rosenthal
FOU | Founder | 68 | 30/04/13 |
| President | 57 | 14/12/21 | |
Marc Grasso
DFI | Director of Finance/CFO | 51 | 06/02/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Louis Lavigne
CHM | Chairman | 75 | 30/09/18 |
Richard Scheller
BRD | Director/Board Member | 70 | 30/09/18 |
Arnon Rosenthal
FOU | Founder | 68 | 30/04/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.70% | 16 M€ | -8.49% | ||
| 0.06% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 5.25 | +9.15% | 457,391 |
| 25/04/24 | 4.81 | -8.38% | 505,642 |
| 24/04/24 | 5.25 | -1.69% | 401,123 |
| 23/04/24 | 5.34 | +3.29% | 546,558 |
| 22/04/24 | 5.17 | +1.57% | 353,199 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.25
USD
Average target price
16.22
USD
Spread / Average Target
+208.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.21% | 506M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALEC Stock
